Phase IIA Study of the Safety and Tolerability of the Use of Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis

Trial Profile

Phase IIA Study of the Safety and Tolerability of the Use of Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2017

At a glance

  • Drugs Imatinib (Primary)
  • Indications Diffuse scleroderma
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Mar 2017 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last January 2013).
    • 15 Mar 2017 Results of proteomic analysis of sera collected from two phase II trial including this published in The Journal of Rheumatology
    • 10 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top